Marketwire - Pharmaceuticals and Biotech

Patient Enrolment Completed in Phase II Clinical Trial Evaluating Allon's AL-108 in Schizophrenia-Related Cognitive Impairment

Tue, 02 Dec 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 2, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company's proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment. The trial is being managed and funded largely by TURNS (Treatment Units for Research on Neurocognition and Schizophrenia), with support from the U.S. National Institute of Mental Health. Top-line results are expected to be released in 2009.

Caroline Loewy Joins Corcept as Chief Financial Officer

Tue, 02 Dec 2008 09:00:00 EST

MENLO PARK, CA--(Marketwire - December 2, 2008) - Corcept Therapeutics (NASDAQ: CORT) today announced the appointment of Caroline M. Loewy to the position of Chief Financial Officer. She will oversee Corcept's financial operations, business development activities, investor relations, and along with other members of the management team, corporate strategy.

"We are pleased to have a person with Caroline's financial and biopharmaceutical industry expertise join us at Corcept," said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept Therapeutics. "Caroline's broad experience will be valuable to Corcept during this significant period in our Company's evolution, as we move CORLUX toward the market with our two ongoing Phase III programs, and advance our second generation selective GRII antagonists into clinical development."

China Yongxin Pharmaceuticals, Inc. Establishes Retailing Chain Management Head Office to Uniformly Manage Its Growing Base of Chain Drugstores

Tue, 02 Dec 2008 09:00:00 EST

CHANGCHUN, CHINA and LOS ANGELES, CA--(Marketwire - December 2, 2008) - China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or "the Company") (OTCBB: CYXN), a leading distributor and retailer of pharmaceuticals in Northeastern China, announced today that it has recently established a Retailing Chain Management Head Office to uniformly manage its growing base of chain drugstores.

"We established the Retailing Chain Management Head Office to further the implementation of our 5-year strategic development plan for the retailing chain business of China Yongxin," stated Mr. Yongxin Liu, Chairman and CEO of China Yongxin Pharmaceuticals, Inc. "This facility will allow us to plan for the expansion of the retailing chain through all levels, to integrate our resources and methodically execute on rolling out new stores. Concurrently, it will allow us to set up a standardized medicine retailin

CLX Medical, Inc. Announces Close of ThyroTest(R) Acquisition

Tue, 02 Dec 2008 08:50:00 EST

MURRIETA, CA--(Marketwire - December 2, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced the close of the company's acquisition of ThyroTest�, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.

With the close of the transaction, CLX Medical will implement its ThyroTest� marketing program and establish distribution of the product with a national U.S. distributor. ThyroTest� is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.

Adeona Pharmaceuticals and National Neurovision Research Institute (NNRI) Collaborate to Test Flupirtine for Retinitis Pigmentosa

Tue, 02 Dec 2008 08:30:00 EST

NNRI to Fully Fund Research for Retinitis Pigmentosa

SK&A Offers Deeper Intelligence on Office-Based Physicians and Their Medical Practices

Tue, 02 Dec 2008 08:15:00 EST

IRVINE, CA--(Marketwire - December 2, 2008) - SK&A, a leading provider of healthcare information solutions and research, today announced it has added important new targeting variables to its market leading Office-Based Physicians database. As part of its standard telephone verification and survey process, SK&A Research Associates are asking medical offices about the primary and secondary languages their office supports, site office hours, the number of exam rooms, whether or not the office accepts Medicare and Medicaid, whether or not the office is accepting new patients, whether or not the office is using an Electronic Medical Records (EMR) system, and office billing address verification.

Symyx Registration 1.5 Software Provides Out-of-the-Box Chemical Data Management

Tue, 02 Dec 2008 08:00:00 EST

Expands Compound Registration Options, Integrates Chemical and Biological Data

GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme

Tue, 02 Dec 2008 08:00:00 EST

Initial results demonstrate potential of '444 in the treatment of patients with moderate to severe asthma

Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures

Tue, 02 Dec 2008 07:30:00 EST

Company Focuses on Clinical Development Path for LCA, HD and ALS; Cuts Costs by Personnel Reductions and Salary Deferrals and Reductions

Noesis Bursting With Exciting Growth

Tue, 02 Dec 2008 07:00:00 EST

PARSIPPANY, NJ--(Marketwire - December 2, 2008) - Noesis, a professional advertising and promotion unit of CommonHealth whose name is derived from the Greek word meaning "to think," today announced two promotions and three new hires.

CommonHealth (www.commonhealth.com) is the world's leading healthcare-communications network and a WPP (NASDAQ: WPPGY) (www.wpp.com) company.

Biotech REIT Blinks Back: Nearly $700 Million in Capital Construction Investment Is Halted, an Industrial Info News Alert

Tue, 02 Dec 2008 07:00:00 EST

SUGAR LAND, TX--(Marketwire - December 2, 2008) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Real estate investment trusts (REIT) have become increasingly attractive to the life science industry for the financial flexibility they can provide. Funds can be invested into increased research and other needs, rather than the "bricks and mortar" end of business. At the top of the REIT list, in both the public and private sector, is Alexandria Real Estate Equities (NYSE:ARE) (Pasadena, California).

SciClone Pharmaceuticals Appoints Gary Titus as Chief Financial Officer

Tue, 02 Dec 2008 06:30:00 EST

FOSTER CITY, CA--(Marketwire - December 2, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Gary Titus as Chief Financial Officer and Senior Vice President, Finance, effective December 8, 2008. In this position, Mr. Titus will use his significant biotechnology industry experience to lead finance activities and investor relations for the Company as well as oversee human resources, and legal affairs. Mr. Titus will report to Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone.

BioSET Announces Initiation of Clinical Trials for AMPLEX Osteo-Promotive Bone Graft System for Spine Fusion

Tue, 02 Dec 2008 06:00:00 EST

Pilot Studies Initiated in Both the U.S. and Canada, and First Patient Treated

BIOLASE Cuts Quarterly Fixed Costs by $2 Million or 20 Percent

Tue, 02 Dec 2008 06:00:00 EST

Reduces 2009 Quarterly Break Even Point Substantially

Strempel & Partners beraten V�toquinol bei der �bernahme von Ascor Chimici Srl

Tue, 02 Dec 2008 05:03:00 EST

Strempel & Partners Srl, eine in Mailand ans�ssige Corporate-Finance-Firma, ist sehr erfreut, die �bernahme von Ascor Chimici Srl durch ihren an der Euronext notierten Kunden V�toquinol bekannt geben zu d�rfen. Die Transaktion tritt am 1. Dezember 2008 in Kraft. V�toquinol wurde vom Corporate-Finance-Team von Strempel & Partners unter Leitung von David Strempel und Davide Ferrero beraten.

InforSense Partners With the U.K.'s South London and Maudsley NHS Foundation Trust and King's College London to Combat Alzheimer's Disease

Tue, 02 Dec 2008 03:00:00 EST

Translational Research Solution to Help Accelerate Early Diagnosis and Personalized Medicine Treatments

Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

Tue, 02 Dec 2008 01:38:00 EST

GENEVA--(Marketwire - December 2, 2008) - Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. The standard dose of PPI does not control GERD adequately in about 40% of patients. ADX10059 is a first-in-class reflux inhibitor that works by selectively inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation. This approach may lead to a new class of drugs that addresses the causes of GERD rather than the symptoms.

UCB announces start of Phase I study for antibody drug candidate CDP6038

Tue, 02 Dec 2008 01:17:00 EST

BRUSSELS, BELGIUM--(Marketwire - December 2, 2008) -

Brussels (Belgium), December 2, 2008 at 07:00 AM (CET) - UCB announced today that its CDP6038 antibody drug candidate targeting IL-6 has achieved a key milestone as the first subjects have been dosed in its Phase 1 'first in human' study.

Interleukin-6 (IL-6) is one of several cytokines involved in the inflammatory process. CDP6038 is thus part of UCB's long-term commitment to the field of immunology and, in pre-clinical studies, has already shown potential in a number of auto-immune diseases.

Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

Tue, 02 Dec 2008 01:14:00 EST

GENEVA, SWITZERLAND--(Marketwire - December 2, 2008) -

Fran�ais (PDF): http://hugin.info/138017/R/1274456/283439.pdf

Deutsch (PDF): http://hugin.info/138017/R/1274456/283440.pdf

English (PDF): http://hugin.info/138017/R/1274456/283441.pdf

Geneva, Switzerland, 2 December 2008 - Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. The standard dose of PPI does not control GERD adequately in about 40% of patients. ADX10059 is a first-in-class reflux inhibitor that works by selectiv

Pacgen Reports Second Quarter Financial Results

Mon, 01 Dec 2008 21:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 1, 2008) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) today reported financial results from its second fiscal quarter ended September 30, 2008. Amounts unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). Financial Results The Company recorded a net loss of $642,454 ($0.02 per common share) for the three months ended September 30, 2008 ("Q2 2009"), compared to a net loss of $1,544,854 ($0.05 per common share) for the three months ended September 30, 2007 ("Q2 2008"). On a year-to-date basis, the Company recorded a net loss of $1,949,955 ($0.06 per common share), compared to a net loss of $3,339,510 ($0.11 per common share) for the same period in the preceding fiscal year. The decrease in net loss in each of the periods in Q2 2009 and on a year-to-date basis, as compared to the same periods in th

Kearny Ventures Hires Andrew Jensen as Chief Financial Officer

Mon, 01 Dec 2008 19:20:00 EST

SAN FRANCISCO, CA--(Marketwire - December 1, 2008) - Kearny Venture Partners has hired Andrew Jensen as Chief Financial Officer, the firm announced today.

As CFO, Mr. Jensen will oversee investor relations, legal, finance, information technology and human resources, and he will assist the investing team with transaction structuring and financial due diligence. Prior to joining Kearny Ventures, Mr. Jensen was CFO of Liquid Realty Partners, a real-estate secondaries firm, from 2005 to 2008. Before that, he was the Senior Controller of Gryphon Investors and Director of Finance at Sanderling Ventures. Earlier, Mr. Jensen, a certified public accountant, was an audit manager with Arthur Andersen. He has earned his BA in Finance and Accounting with honors from the University of California, Berkeley.

Strempel & Partners assiste V�toquinol nell'acquisizione di Ascor Chimici Srl

Mon, 01 Dec 2008 18:32:00 EST

Strempel & Partners srl, societ� di corporate finance basata a Milano, � lieta di annunciare l'acquisizione di Ascor Chimici srl da parte del proprio cliente, V�toquinol, societa' quotata sul circuito Euronext. La transazione diventa effettiva in data odierna, 1� Dicembre 2008. V�toquinol � stata assistita dal team di corporate finance di Strempel & Partners guidato da David Strempel e Davide Ferrero .

Theravance Announces New Employment Inducement Awards

Mon, 01 Dec 2008 18:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwire - December 1, 2008) - Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to five new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of equity awards to new employees. In accordance with Nasdaq rules, these grants were made under an equity incentive plan without stockholder approval. Nasdaq rules require a public announcement of equity awards to be made under this type of plan. Five employees were granted equity awards to acquire an aggregate of 171,376 shares of the Company's common stock, of which 166,000 are stock options and 5,376 are restricted stock unit awards. These equity awards vest over approximately four years and the options expire in 10 years assum

Strempel & Partners Advises V�toquinol in Acquiring Ascor Chimici Srl

Mon, 01 Dec 2008 18:27:00 EST

Strempel & Partners Srl, a Milan-Based Corporate Finance Firm Is Pleased to Announce the Acquisition by Its Client V�toquinol (Listed on the Euronext Exchange) of Ascor Chimici Srl; The Transaction Takes Effect on December 1, 2008; V�toquinol Was Advised by Strempel & Partners' Corporate Finance Team Led by David Strempel and Davide Ferrero

Lydall Acquires New Technology Platform in The Netherlands

Mon, 01 Dec 2008 17:10:00 EST

MANCHESTER, CT--(Marketwire - December 1, 2008) - Lydall, Inc. (NYSE: LDL) -- Lydall today announced its acquisition of DSM Solutech B.V. from Royal DSM N.V. Solutech, located in The Netherlands, has developed Solupor� specialty microporous membranes which will enhance Lydall's product offering in air & liquid filtration applications.

Solutech will be integrated into Lydall's Performance Materials business. Through the third quarter of 2008, Performance Materials represented 36% of Lydall's net sales and 64% of business unit operating income and had the highest operating margin of Lydall's business units. Its filtration business participates in the $2.3 billion global nonwoven filter media market which has recently seen strong global growth due to stricter environmental and product purity laws and requirements.

Endo Announces Resignation of Board Member

Mon, 01 Dec 2008 16:30:00 EST

CHADDS FORD, PA--(Marketwire - December 1, 2008) - Endo Pharmaceuticals (NASDAQ: ENDP) announced today the resignation of George F. Horner, III as a member of the company's board of directors. Mr. Horner has been a director of Endo since August 2006 and has resigned to pursue other business opportunities. The resignation will be effective January 1st, 2009.

"The board and I greatly appreciate George's contributions to Endo's growth and success and wish him well in his future endeavors," said David Holveck, president and chief executive officer of Endo.

Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of Hematology Annual Meeting and Exposition

Mon, 01 Dec 2008 16:00:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwire - December 1, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 6-9, 2008 at the Moscone Center in San Francisco, California. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.

MD&DI Wins National Gold Azbee Award From ASBPE for 'Neurotechnology Article'

Mon, 01 Dec 2008 14:05:00 EST

LOS ANGELES, CA--(Marketwire - December 1, 2008) - Medical Device & Diagnostic Industry (MD&DI), a Canon Communications publication, and Sherrie Conroy, Editor-in-Chief, were recently honored with a prestigious National Gold Azbee award for Best Feature Article in 2007 by the American Society of Business Publication Editors (A.S.B.P.E). The winning article, "Neurotechnology Offers Relief and Recovery," written by Conroy, was published in the July 2007 issue of MD&DI.

Vanguard Pharmaceutical Corporation Negotiates Telomerase Delivery Technology

Mon, 01 Dec 2008 11:49:00 EST

SAN ANTONIO, TX--(Marketwire - December 1, 2008) - Vanguard Pharmaceutical Corp. (PINKSHEETS: VGPH), a company who has joined the fight against cancer by selling affordable generic oncology drugs and researching noninvasive cures for cancer, is now in negotiations with a biotechnology company who has an effective delivery method for telomerase therapies. Vanguard is negotiating to either acquire or gain a significant stake in the company.

Portland Press Limited Extends Three Year Relationship With Aptara

Mon, 01 Dec 2008 11:08:00 EST

Aptara Delivers High Quality, Cost-Efficient Solution to Not-for-Profit Publisher

Chembio Donates HIV Tests to Support World AIDS Day 2008 Testing Initiative

Mon, 01 Dec 2008 09:00:00 EST

MEDFORD, NY--(Marketwire - December 1, 2008) - Chembio Diagnostics, Inc. (OTCBB: CEMI) ("Chembio" or the "Company") joined AIDS Healthcare Foundation (AHF) in the World AIDS Day 2008 global effort to test one million people from November 26 through December 1, 2008. Based in Los Angeles, AHF provides state-of-the-art medicines and advocacy to over 85,000 people in 22 countries and is the nation's largest provider of HIV/AIDS medical care. Chembio is supporting these efforts by providing approximately 20,000 HIV 1/2 STAT-PAK� tests to testing programs in 3 countries. Chembio's HIV 1/2 STAT-PAK� and HIV 1/2 STAT-PAK� Dipstick tests are ideally suited for point-of-care testing with a simple test protocol, long shelf life, minimum sample requirements for venous or finger-stick whole-blood, plasma or serum, test results in < 10 minutes and room temperature storage requirements. Chembio has also complete

Pyng Medical Reports Record Sales of $6.5 Million in Fiscal 2008

Mon, 01 Dec 2008 09:00:00 EST

Pyng Achieves 36% Increase In Revenue over Fiscal 2007 and Gross Margin of 70%

Daxor Announces Special Year-End Dividend

Mon, 01 Dec 2008 08:30:00 EST

NEW YORK, NY--(Marketwire - December 1, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced that The Board of Directors has voted to declare a special year-end dividend of $1.00 per share. The dividend will be paid to shareholders of record as of December 12, 2008. The dividend will be paid on Tuesday, December 30, 2008.

The Company previously paid quarterly dividends of $0.25 per share in 2008 on August 27th and November 26th. Prior to 2008, the Company last paid a dividend in 1996.

Prana Provides Update on Research and Development Programs at AGM

Mon, 01 Dec 2008 08:30:00 EST

MELBOURNE, AUSTRALIA--(Marketwire - December 1, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT) today provided an update of highlights of current and future activities of the Company at the Annual General Meeting.

PBT2 for Alzheimer's Disease

Chairman and CEO, Geoffrey Kempler, discussed the success of Prana's Phase IIa clinical trial of PBT2 in early Alzheimer's Disease and affirmed that the Company plans to enter larger clinical trials and advance towards commercialization.

Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services

Mon, 01 Dec 2008 08:18:00 EST

BUFFALO, NY--(Marketwire - December 1, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Michelle Ross, DVM, M.S, Ph.D., as Senior Vice President of Public Health and Government Services, with responsibility for commercialization of military and public health medical emergencies applications. Dr. Ross joins Cleveland BioLabs while remaining a Senior Partner for Biodefense and Public Health Programs with Martin, Blanck & Associates, a federal health services consulting firm.

Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells

Mon, 01 Dec 2008 08:10:00 EST

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2008) - Pharmaceutical company Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work performed in collaboration with a Yale University research team led by Associate Professor Gil Mor, MD, PhD, has revealed its novel mTOR inhibitor NV-128 has the potential to act against cancer stem cells in addition to rapidly proliferating cells in established solid tumors.

Marshall Edwards, Inc. Files IND Application for Triphendiol

Mon, 01 Dec 2008 08:10:00 EST

NEW CANAAN, CT--(Marketwire - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an Investigative New Drug (IND) approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine. The IND application is to enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.

REMINDER: MAKOplasty(R) Robotic Arm Partial Knee Resurfacing -- A New Level of Precision

Mon, 01 Dec 2008 07:15:00 EST

OR-Live Webcast From St. Elizabeth Community Hospital: December 1, 2008, 3:00 PM PST

Auxilium Pharmaceuticals, Inc. Announces Distribution and License Agreement for Testim(R) in Europe With Ferring Pharmaceuticals

Mon, 01 Dec 2008 07:00:00 EST

MALVERN, PA and SAINT-PREX, SWITZERLAND--(Marketwire - December 1, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Ferring International S.A. today announced an exclusive agreement between them for the European distribution and license rights to Testim�, a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism.

"We are very pleased to have Ferring as our partner, given the strength of their European specialty urology and endocrinology franchises, their existing commercial infrastructure across Europe, and the successful track record they have established in commercializing differentiated products in the European Union," said Armando Anido, Chief Executive Officer and President of Auxilium. "This agreement enables us to bring our innovative testosterone replacement product to patients in all of the 15 countries where Testim has been approved and potentially in

Imaging3 CEO Opens RSNA 2008 Conference With New Images and Interview With Leading Trade Publication

Mon, 01 Dec 2008 07:00:00 EST

CHICAGO, IL--(Marketwire - December 1, 2008) - Imaging3T, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced the release of the company's newest imaging software at the 94th annual Radiological Society of North America (RSNA) conference and trade show.

Dean Janes, CEO of Imaging3, summarized the positive reception that Imaging3 and the Dominion Volumetric Imaging Scanner (DViS) received on the opening day of the conference in an interview with Merion Publications, Inc., a leading publisher of healthcare and medical imaging news for radiology professionals. "The publisher's interviews at RSNA are focused on new innovations that hold promise to dramatically improve patient care and safety and we are very gratified to be selected by Merion Publishing for these reasons," stated Mr. Janes.

DOR BioPharma Receives $1.5 Million From Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec(R) Strategic Alliance

Mon, 01 Dec 2008 07:00:00 EST

EWING, NJ--(Marketwire - December 1, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that it has received $1.5 million under a letter of intent with Sigma-Tau Pharmaceuticals, Inc. ("Sigma-Tau"), which grants Sigma-Tau an exclusive right to negotiate terms and conditions for a possible business transaction or strategic alliance regarding orBec� (oral beclomethasone dipropionate or oral BDP) and potentially other DOR pipeline compounds until March 1, 2009.

AngioChem to Present at the 20th Annual Piper Jaffray Health Care Conference

Mon, 01 Dec 2008 07:00:00 EST

MONTREAL, CANADA--(Marketwire - Dec. 1, 2008) - AngioChem will present at the upcoming 20th Annual Piper Jaffray Heathcare Conference being held in New York on December 2-3, 2008. The presentation by Dr. Jean-Paul Castaigne MD, MBA, President and Chief Executive Officer, will be on Tuesday, December 2nd at 4:10 pm. Dr. Jean Paul Castaigne will provide a corporate overview and an update on the two on-going internal programs with anti-cancer agents and peptides as well as on the external research collaborations on siRNA and MAbs with a leader in the field.

Protherics PLC announces Offer Update

Mon, 01 Dec 2008 06:36:00 EST

Cheshire, UK--(Marketwire - December 1, 2008) -


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, IN
OR INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION


London, 1 December 2008

PROTHERICS PLC ("PROTHERICS")


Offer Update: Court sanction of Scheme of Arrangement


Protherics (LSE: PTI) and BTG plc ("BTG") (LSE: BGC) are pleased to
announce that the High Court of Justice in England and Wales has today
made an order sanctioning the Scheme of Arrangement by which BTG's
Acquisition of Protherics is being implemented.


In order for the Scheme to become effective in accordance with its
terms, the Court will now need to confirm the associated Reduction of
Capital at the Reduction Court Hearing. This hearing will take place on
3 December 2008. Following the confirmation

ImmuneRegen(R) Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board

Mon, 01 Dec 2008 06:30:00 EST

Company Gains Further Scientific and Biotech Business Expertise to Accelerate Development of, and the Opportunity for Clinical Trials for, New Wound Care Drug

Register for BioPartnering North America (BPN) Now and Save CAD $450 Off the General Registration Rate

Mon, 01 Dec 2008 03:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 1, 2008) - Technology Vision Group LLC (TVG) is pleased to announce the availability of the early registration rate for the 7th Annual BioPartnering North America (BPN) conference, to be held in Vancouver, B.C., Canada, on February 8-10, 2009. Register for BPN now at http://www.techvision.com/bpn/registration/ and save CAD $450 off the general registration rate. Pharmaceutical companies may also be eligible to receive two registrations for the price of one! Certain restrictions apply. Contact registration@techvision.com for details.

Global Needlestick Prevention Group Honors Award Recipients as It Marks 7th Annual International Sharps Injury Prevention Awareness Month

Mon, 01 Dec 2008 01:00:00 EST

SALT LAKE CITY, UT--(Marketwire - December 1, 2008) - ISIPS, the first international sharps injury prevention group, announced that five recipients are being honored for reducing sharps injuries with a Sharps Injury Prevention Award with an additional 9 recipients receiving honorable mention awards. These awards are part of the International Sharps Injury Prevention Awareness Month activities being commemorated during December, 2008 starting with World AIDS Day, December 1st.

A number of very worthy individuals were nominated for the ISIPS 2008 International Sharps Injury Prevention Awards. Nominations were reviewed by a nominating committee, comprised of representatives from Terumo Medical, Covidien, Retractable Technologies Inc., Qlicksmart, Smartstream Pty Ltd, Managing Infection Control magazine and the International Sharps Injury Prevention Society (ISIPS). We are grateful to these organizations for sponsoring the awards this year.

PharmEng Reports Reduced Cash Burn, Financing Update, Strategic Update, Board Member Additions, and Third Quarter Earnings for 2008

Sun, 30 Nov 2008 23:40:00 EST

TORONTO, ONTARIO--(Marketwire - Nov. 30, 2008) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today reported its results for the period ended September 30, 2008. The Company also announced Board changes and provided an update on the strategic plan involving the integration of the newly commissioned Sydney facility. Readers are encouraged to review the Company's complete Interim Consolidated Financial Statements and accompanying Management's Discussion & Analysis which are available under the "investors" section of its website at www.pharmeng.com and on SEDAR at www.sedar.com.

Paragon Pharmacies Announces 12 Month Revenue of $83.718 Million- an Increase of 26.6 Per Cent

Sun, 30 Nov 2008 22:49:00 EST

KELOWNA, BRITISH COLUMBIA--(Marketwire - Nov. 30, 2008) - Paragon Pharmacies Limited ("Paragon" or the "Corporation") (TSX VENTURE:PGN) today reported its financial results for the fiscal year ended August 31, 2008. Revenue was $83.718 million in 2008, an increase of 26.6 per cent or $17.572 million over 2007. The increase was a result of growth in same store revenue and new revenue from the acquisition of one retail pharmacy and three central fill pharmacies during the year. Total same store revenue was up six per cent (excluding two home healthcare stores), of which pharmacy was up eleven per cent and front store (all non-pharmacy revenue) was flat for the year. During the year, store operations generated $5.878 million in operating income compared to $4.787 million in 2007.

Cryobanks International and Becoming Mom Pregnancy Spa & Ultrasound Imaging Center Team Up to Educate Moms About Umbilical Cord Blood

Sun, 30 Nov 2008 01:00:00 EST

ALTAMONTE SPRINGS, FL--(Marketwire - November 30, 2008) - Cryobanks International Inc., a leader in the collection, processing, and banking of umbilical cord blood, is pleased to announce its new partnership with Becoming Mom Pregnancy Spa & Imaging Center located in Mason, OH, a Cincinnati, OH suburb.

Through this partnership, Becoming Mom will add umbilical cord blood storage and donation to its long list of specialty services all which promote a healthy pregnancy for its clients. Becoming Mom will be taking an active role in educating their members about their cord blood options while in the comfort of the Becoming Mom Spa environment. Through this program, Becoming Mom Members will be able to donate their cord blood free of cost. Or if they feel private storage is the better option, their Becoming Mom Spa Membership will earn them a discount on Cryobanks International's initial processing and storage fee.

Med BioGene Reports Financial Results for the Third Quarter 2008

Fri, 28 Nov 2008 21:56:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 28, 2008) - Med BioGene Inc. (TSX VENTURE:MBI) today reported its financial results for the third quarter of 2008. Erinn Broshko, MBI's Chief Executive Officer stated: "This is an important time for the company as we prepare for the U.S. launch of LungExpress Dx(TM) in mid 2009. LungExpress Dx(TM), our lead product under development, is a gene expression-based test for early stage non-small-cell lung cancer that provides valuable information regarding each patient's prognosis in order to more effectively guide treatment and improve the selection of patients for chemotherapy following surgical removal of their cancerous tumour. Over the last quarter, we broadened our commercialization team and continued to execute upon our strategy for the successful introduction of LungExpress Dx(TM). Furthermore, we completed a $1.8 million financing in challenging global financial markets to facilitate the establishment of our commercial operations."

BioSyent Releases Financial Results-Third Quarter 2008

Fri, 28 Nov 2008 16:00:00 EST

MISSISSAUGA, ONTARIO,--(Marketwire - Nov. 28, 2008) - BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today released a summary of its financial results for the third quarter 2008. Sales decreased by 8.9% from $1,050,013 in first nine months of 2007 to $956,414 in first nine months of 2008. The company incurred a loss of ($118,363) in the first nine months of 2008 compared to a gain of $31,410 in first nine months of 2007. This loss is predominantly due to the higher pharmaceutical operating expenses for the establishment of the hospital division and the launch of Ciprofloxacin Injection, which was first shipped in May 2008.

Laboratoires Paladin et GlaxoSmithKline Inc. signent un accord relatif au Dexedrine(MD), faisant place � une nouvelle relation strat�gique

Fri, 28 Nov 2008 14:37:00 EST

MONTREAL, CANADA--(Marketwire - 28 nov. 2008) - Laboratoires Paladin Inc. (TSX:PLB), chef de file de l'industrie pharmaceutique sp�cialis�e au Canada, a annonc� aujourd'hui la signature d'un accord avec GlaxoSmithKline Inc. (GSK) et Glaxo Group Limited, nommant Laboratoires Paladin Inc. en tant que distributeur exclusif de Dexedrine(MD) (sulfate de dexamph�tamine) au Canada pour une p�riode de trois ans, � la suite de laquelle Paladin aura l'option d'acheter tous les droits restants au produit dans l'ensemble du Canada. GSK offrira des services d'appui � la distribution au cours d'une p�riode int�rimaire. Cet accord marque aussi le commencement d'une relation strat�gique avec GSK dans le cadre de laquelle Laboratoires Paladin Inc. aura le droit essentiel de s'associer � GSK en ce qui a trait � plusieurs produits que GSK pourrait autoriser ou dont GSK pourrait se d�partir au Canada. Les modalit�s financi�res de l'op�ration n'ont pas �t� divulgu�es.

Paladin Labs and GlaxoSmithKline Inc. Sign Agreement on Dexedrine(R) and Mark Start of a New Strategic Relationship

Fri, 28 Nov 2008 14:36:00 EST

MONTREAL, CANADA--(Marketwire - Nov. 28, 2008) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced it is signing an agreement with GlaxoSmithKline Inc. (GSK) and Glaxo Group Limited that appoints Paladin Labs Inc. as the exclusive distributor of Dexedrine(R) (dextroamphetamine sulfate) within Canada for a period of three years, with an option for Paladin to purchase all remaining rights to the product in Canada at the end of that period. GSK will be providing certain distribution support services for an interim period. The agreement also marks the start of a strategic relationship with GSK whereby Paladin Labs Inc. will have the first right to partner with GSK on a number of products that GSK may choose to license or divest in Canada. Financial terms of the transaction were not disclosed.

Smith & Nephew Plc - Total Voting Rights

Fri, 28 Nov 2008 11:48:00 EST

LONDON, UK--(Marketwire - November 28, 2008) -


Smith & Nephew plc - Voting Rights and Capital

28 November 2008

In conformity with Rule 5.6.1 of the FSA's Disclosure
and Transparency Rules, we notify the market that as at 28
November 2008:

Smith & Nephew plc's issued share capital with voting rights consists
of 883,084,314 ordinary shares of US20c each.  

66,634,911 ordinary shares are held in treasury, and are not included
in the above figure.

883,084,314 ordinary shares may be used by shareholders for calculating
if they are required to notify their interest in, or change to their
interest in, the Company under the FSA's Disclosure and Transparency
Rules.

Paul Chambers
Company Secretary

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Great Lakes Biogas Technolgies Inc. Announces New Company Transfer Agency

Fri, 28 Nov 2008 10:56:00 EST

MARIETTA, GA--(Marketwire - November 28, 2008) - Great Lakes Biogas Technologies Inc. (PINKSHEETS: GLBS) (FRANKFURT: CS4) has appointed Knightsbridge Assurance Inc. as the company's new transfer of record. Any correspondence or business sent to the old transfer will automatically be forwarded to Knightsbridge Assurance for processing. GLBS issued and outstanding shares to date are 20,849,887.

Acceleware Corp. Announces Third Quarter Results

Fri, 28 Nov 2008 07:00:00 EST

CALGARY, ALBERTA--(Marketwire - Nov. 28, 2008) - Acceleware Corp. (the "Corporation" or "Acceleware") (TSX VENTURE:AXE) reported today its financial results for the period ended September 30, 2008. /T/ Third Quarter 2008 Financial Highlights 3 months ended 3 months ended 9 months ended 9 months ended Sep 30, 2008 Sep 30, 2007 Sep 30, 2008 Sep 30, 2007 Revenue $ 472,620 $ 644,023 $ 2,900,910 $ 1,606,924 Net Loss $ 3,108,208 $ 1,795,667 $ 8,181,266 $ 4,616,323 L

Active Biotech's election committee appointed

Fri, 28 Nov 2008 04:36:00 EST

LUND, SWEDEN--(Marketwire - November 28, 2008) - In accordance with the decision by the Annual General Meeting on May 7, 2008, the election committee shall consist of representatives from the three largest shareholders as at the end of October and the Chairman of the Board.

The election committee for the next Board election consists of Johnny Sommarlund for MGA Holding, Tomas Billing for Nordstjernan and Ulf Str�msten for Catella funds.

Headed by the Chairman of the Board, Mats Arnh�g, the election committee will prepare a proposal for the composition of the Board to be presented to the Annual General Meeting on May 7, 2009.

Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2008

Thu, 27 Nov 2008 17:30:00 EST

TORONTO, ONTARIO--(Marketwire - Nov. 27, 2008) - Cannasat Therapeutics Inc. (TSX VENTURE:CTH), a CNS (Central Nervous System) drug development company, today announced its results for the nine months ended September 30, 2008. OPERATIONAL HIGHLIGHTS - Completed work with IntelGenx Corp. to refine CAT 310 prototype formulations. CAT 310 is a potential treatment for patients with neuropathic pain, nausea/vomiting and other conditions, and is on track to commence Phase 1(b) clinical testing in Q1 2009.

Ceapro annonce une augmentation de ses ventes pour son troisi�me trimestre et la p�riode de neuf mois de 2008

Thu, 27 Nov 2008 09:25:00 EST

EDMONTON, ALBERTA, CANADA--(Marketwire - 27 nov. 2008) - Ceapro Inc. (TSX CROISSANCE:CZO) a annonc� aujourd'hui une augmentation de 47 % de ses ventes pour le troisi�me trimestre termin� le 30 septembre 2008. Le chiffre d'affaires a atteint 871 000 $ comparativement � 591 000 $ pour la m�me p�riode l'ann�e derni�re. Ces chiffres ont �t� r�alis�s en d�pit d'un taux de change plus faible du dollar am�ricain lors des neuf premiers mois de 2008 et d'une interruption de l'approvisionnement des mati�res premi�res suite � une inondation dans le Midwest des Etats-Unis pendant les mois de juillet et d'ao�t. Dans l'ensemble, il existe une demande croissante pour les ingr�dients biologiques et naturels actifs de Ceapro, et la Soci�t� a pris plusieurs mesures afin d'augmenter les marges brutes et de r�pondre � la demande croissante pr�vue pour 2009.

Ceapro Reports Increased Sales in Third Quarter and Nine-Month Period of 2008

Thu, 27 Nov 2008 07:30:00 EST

EDMONTON, ALBERTA, CANADA--(Marketwire - Nov. 27, 2008) - Ceapro Inc. (TSX VENTURE:CZO) today reported 47% increase in sales for the third quarter ended September 30, 2008. Revenues reached $871,000 compared with $591,000 in the same period last year. This was achieved despite a lower US dollar exchange rate for the first nine months of 2008 and an interruption in the supply of key raw material due to flooding in the Midwest U.S. during July and August. Globally, there is a growing demand for Ceapro's natural and organic active ingredients and the Company has taken several actions to increase gross margins and to be in a position to respond to an expected overall increased demand in 2009.

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist

Thu, 27 Nov 2008 05:16:00 EST

COPENHAGEN, DENMARK--(Marketwire - November 27, 2008) -

Summary:

Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.

Deal terms

Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sub-licensees. In return Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones for an undisclosed amount. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma has retains the

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonist

Thu, 27 Nov 2008 04:41:00 EST

COPENHAGEN, DENMARK--(Marketwire - November 27, 2008) -

Summary:

Deal terms

Pr�sentation de MethylGene lors de conf�rences aux investisseurs

Wed, 26 Nov 2008 14:00:00 EST

MONTREAL, QUEBEC--(Marketwire - 26 nov. 2008) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui que son pr�sident et chef de la direction, Donald F. Corcoran, participera prochainement � deux conf�rences aux investisseurs � New York : l'une commandit�e par Piper Jaffray, l'autre par RBC March�s des Capitaux. M. Corcoran fera une pr�sentation � la 20e conf�rence annuelle Piper Jaffray du secteur m�dical le mardi 2 d�cembre � 11h30 (HE). De plus, M. Corcoran participera le jeudi 11 d�cembre � 8h00 (HE) � une table ronde intitul�e "Se battre contre le cancer" ("Waging A Battle Against Cancer"), lors de la conf�rence 2008 RBC March�s des Capitaux du secteur m�dical.

MethylGene to Present at Investor Conferences

Wed, 26 Nov 2008 14:00:00 EST

MONTREAL, QUEBEC--(Marketwire - Nov. 26, 2008) - MethylGene Inc. (TSX:MYG) today announced that Donald F. Corcoran, President and Chief Executive Officer, will participate in two upcoming investor conferences in New York, one sponsored by Piper Jaffray and the other by RBC Capital Markets. Mr. Corcoran will present at the 20th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2nd at 11:30 a.m. EST. In addition, Mr. Corcoran will participate in a panel discussion entitled, "Waging A Battle Against Cancer" at the RBC Capital Markets 2008 Healthcare Conference on Thursday, December 11th at 8:00 a.m. EST.

Antisoma to present at Piper Jaffray Conference

Wed, 26 Nov 2008 11:55:00 EST

Antisoma to present at Piper Jaffray Annual Healthcare Conference in New York

MedaSorb Technologies' Board Member, Edward Jones M.D., Elected President of the Renal Physicians Association

Wed, 26 Nov 2008 11:31:00 EST

MONMOUTH JUNCTION, NJ--(Marketwire - November 26, 2008) - MedaSorb Technologies Corporation (OTCBB: MSBT) is pleased to recognize the election of its Director, Edward Jones M.D. to President of the Renal Physicians Association. Dr. Jones is an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital. Dr. Jones is currently president elect and will officially take over as president in 2009.

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Wed, 26 Nov 2008 02:01:00 EST

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

FDA issues Complete Response Letter for ceftobiprole

Wed, 26 Nov 2008 01:31:00 EST

BASEL, SWITZERLAND--(Marketwire - November 26, 2008) - Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), a Complete Response Letter for ceftobiprole for the treatment of complicated skin and skin structure infections including diabetic foot infections.

Ceftobiprole showed in two large multinational, double-blind, randomized phase III clinical studies, that it was effective, as demonstrated by meeting the primary endpoint using a 10% non-inferiority margin. A safety profile consistent with the cephalosporin class of antibiotics was demonstrated. Ceftobiprole has been approved or recommended for approval in a number of territories including the European Union.

GENEART receives major contract from the Wellcome Trust Sanger Institute

Wed, 26 Nov 2008 01:00:00 EST

REGENSBURG, GERMANY--(Marketwire - November 26, 2008) -

- The  Wellcome Trust  Sanger Institute  awards a  major contract  on
synthesizing up to 600 genes over the next 10 months to GENEART
- The supplied  genes will  be used in  the research  program of  the
Wellcome Trust Sanger Institute
- The research program's goal  is to identify mechanisms involved  in
defined genetic and infectious diseases

Regensburg, November 26, 2008 - GENEART AG, world market leader for gene synthesis and specialist in Synthetic Biology, announces the closing of a major contract with the Wellcome Trust Sanger Institute, UK. GENEART will synthesize up to 600 tailor-made genes for the Wellcome Trust Sanger Institute's research program under this contract. The genes will be used to identify mechanisms involved in defined genetic and infectious disease. The terms of the agreement were not disclosed.

Stem Cell Therapeutics Corp. Announces Third Quarter 2008 Financial Results and Provides Corporate Update

Tue, 25 Nov 2008 18:25:00 EST

CALGARY, ALBERTA--(Marketwire - Nov. 25, 2008) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) today announced its financial results for the period ended September 30, 2008.

Selected Highlights

SCT accomplished the following selected achievements during the third quarter of 2008 and up to November 25, 2008:

- On July 7, 2008, SCT announced the issuance of two keystone prolactin patents. The U.S. patent, numbered 7,393,830 and entitled "Prolactin induced increase in neural stem cell numbers" was issued July 1, 2008. The Australian patent, numbered 2002325711 and entitled "Prolactin induced increase in neural stem cell numbers and therapeutical use thereof" was issued January 10, 2008. These are the first patents to issue in this patent family. These patents cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection. We have the exclusive right to the

Medistem Suspends Filing Reports With Securities and Exchange Commission

Tue, 25 Nov 2008 18:03:00 EST

Decision Expected to Preserve Capital and Focus Efforts on Core Research and Development

Canadian Pharmacists Association: Recommendations from Competition Bureau Cover Familiar Ground

Tue, 25 Nov 2008 16:42:00 EST

OTTAWA, ONTARIO--(Marketwire - Nov. 25, 2008) - In a report presented today by Sheridan Scott, Commissioner, Competition Bureau, at the Economic Club of Toronto, the Competition Bureau advocated for efforts to be made to change the way generic drugs are paid for in an effort to pass benefits on to payers or consumers. Warren Meek, President of the Canadian Pharmacists Association, said "pharmacists will welcome the view expressed by Ms. Scott that provinces should set up a framework to reimburse pharmacists directly for new services that provide benefits to consumers rather than rely on professional allowances from generic manufacturers."

Toxin Alert Notice of Default Update

Tue, 25 Nov 2008 14:46:00 EST

TORONTO, ONTARIO--(Marketwire - Nov. 25, 2008) - Toxin Alert Inc. (TSX VENTURE:TOX) (the "Company") was unable to file its audited financial statements and other material for the fiscal year ended June 30, 2008 by the statutory deadline of October 29, 2008 and a Management Cease Trade Order was issued by the relevant securities authorities on October 29, 2008. This Default Status Report is issued pursuant to National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Alzheimer's Drug Discovery Foundation Funds Varinel to Develop Drugs for Neurodegenerative Disease

Tue, 25 Nov 2008 14:40:00 EST

NEW YORK, NY--(Marketwire - November 25, 2008) - The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it provided a grant of $185,000 to Varinel, Inc., an emerging pharmaceutical company dedicated to developing drugs that can prevent neuronal degeneration and improve brain function. The grant will assist Varinel in advancing the preclinical development of its multifunctional lead compounds, VAR10300 (also known as M30).

VAR10300 was tested successfully in cellular and animal models of Alzheimer's Disease (AD) reducing oxidative damage to mouse brain cells caused by iron-catalyzed free radical reactions and providing novel neuroprotective activity. The compound also improves levels of neurotransmitters, supports the growth of new neurons, and prevents cell death in preclinical models.

RxElite, Inc. and Minrad International, Inc. Terminate Distributor Agreement

Tue, 25 Nov 2008 12:21:00 EST

MERIDIAN, ID--(Marketwire - November 25, 2008) - RxElite, Inc. (OTCBB: RXEI) announced today that its manufacturing and distribution agreement with Minrad International, Inc. has been terminated. The termination of the manufacturing and distribution agreement allows RxElite to supply anesthetic gas products to its customers from alternative sources.

RxElite will continue to supply products to its customers from existing inventory while working through supply arrangements from alternative sources. RxElite will work closely with its customers and vendors to ensure an ongoing supply of RxElite's key anesthetic gas products.

Are You One of the 260 Million Americans Who Needs Flu Vaccine?

Tue, 25 Nov 2008 11:00:00 EST

National Influenza Vaccination Week Is December 8-14

Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense(TM) Formulation

Tue, 25 Nov 2008 09:41:00 EST

CARLSBAD, CA--(Marketwire - November 25, 2008) - Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced that it received notice of a successful EPA-F.I.F.R.A. registration from its exclusive toll manufacturer of NanoFense, a proprietary antimicrobial nanoparticle formulation developed by ANI to coat or impregnate virtually any air filter media. The completed registration positions Applied Nanoscience to supply their patent-pending silver nanoparticle "coating" to air filtration companies around the world via licensure.